Arul Chinnaiyan, MD, PhD

 Arul Chinnaiyan, MD, PhD
S P Hicks Endowed Professor of Pathology
Section Head, Michigan Center for Translational Pathology
Professor of Pathology and Professor of Urology
Medical School
[email protected]
Available to mentor
Arul Chinnaiyan, MD, PhD
Arul Chinnaiyan, MD, PhD
Professor
  • Center Memberships
  • Recent Publications

  • Manage Your Profile

    • Center Memberships
    • Center Member
      MM-PKUHSC Joint Institute
    • Center Member
      AI and Digital Health Innovation
    • Center Member
      Taubman Institute
    • Center Member
      Global REACH
    • Center Member
      Rogel Cancer Center
    • Center Member
      Center for Computational Medicine and Bioinformatics

    Recent Publications

     See All Publications
    • Journal Article
      A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.
      Wang X, Liu W, Yang J, Tien JC-Y, Chang Y, Mannan R, Mahapatra S, Zhou Y, Gan L, Cao X, Zhou J, Zhang Y, Shaker S, Huang Y, Qiao H, Hamadeh R, Ervine G, Wang C, Su F, Wang R, Xiao L, Sudharshan RR, Rao A, Nikolovska-Coleska Z, Stephens C, Pan L, Chou JJ, Sahu D, Stuckey J, Wang Z, Ding K, Chinnaiyan AM. Proc Natl Acad Sci U S A, 2026 Jul 14; 123 (28): e2537437123 DOI:10.1073/pnas.2537437123
      PMID: 42412946
    • Journal Article
      Optimizing Sequential Decision Rules for Prostate Cancer Biopsy Management: A Multi-Objective Statistical Framework
      Qiu J, Zhao Y-Q, Wei J, Chinnaiyan AM, Tosoian J, Zheng Y. Journal of the American Statistical Association, 2026 Jul 4; ahead-of-print (ahead-of-print): 1 - 13. DOI:10.1080/01621459.2026.2661377
    • Preprint
      A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer
      Zheng Y, Cheng C, Cao Y, Cruz G, Zhang Y, Paturu R, Mahapatra S, Hu J, Mannan R, Karabürk H, Bhattacharyya R, Yin Y, Zhao Y, Liu W, Cao X, Xue H, Li C, Wang Z, Miner SJ, Vaishampayan U, Sahai V, Weisman LS, Ding K, Lyssiotis CA, Wang Y, Qiao Y, Chinnaiyan AM. 2026 Jun 21; bioRxiv, DOI:10.64898/2026.06.15.732391
    • Additional Scholarship
      Supplementary Figure S1 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
      Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu Y-M, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. 2026 Jun 17; DOI:10.1158/2159-8290.32700772
    • Additional Scholarship
      Supplementary Figure S10 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
      Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu Y-M, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. 2026 Jun 17; DOI:10.1158/2159-8290.32700769
    • Additional Scholarship
      Supplementary Figure S2 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
      Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu Y-M, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. 2026 Jun 17; DOI:10.1158/2159-8290.32700763
    • Additional Scholarship
      Supplementary Figure S3 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
      Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu Y-M, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. 2026 Jun 17; DOI:10.1158/2159-8290.32700760
    • Additional Scholarship
      Supplementary Figure S4 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
      Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu Y-M, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. 2026 Jun 17; DOI:10.1158/2159-8290.32700754

    Featured News & Stories

         close up of cells blue purple pink
    Health Lab

    Researchers create new path to target hard-to-drug prostate cancer protein

    University of Michigan researchers have identified a specific pocket within ERG, a driver of prostate cancer, and have developed a small molecule probe, called PBITE-1, that can bind to it.
         Illustration of tumor formation inside a globe as researchers look on
    Illuminate

    The Answers in the Epigenome

    Rogel Cancer Center researchers study how epigenetics regulates cancer-related genes, aiming to improve therapies, prevention strategies, and patient outcomes.
         microscope drawing yellow navy
    Health Lab

    Researchers identify new therapeutic target for neuroendocrine tumors in the gastrointestinal tract

    University of Michigan researchers have identified a new target that can suppress tumor growth. Their findings may lead to new treatment methods for gastroenteropancreatic neuroendocrine tumors.
         lots of the same fish swimming inside blue teal water
    Health Lab

    Additional testing can improve kidney cancer diagnosis

    Michigan Medicine findings suggest further investigation of FISH-negative tests for renal cell carcinoma could lead to more accurate diagnosis.
         blue and white pill being broken and dots falling out in middle
    Health Lab

    Researchers find a targeted approach to shut down prostate cancer growth

    Study shows a novel compound that degrades key proteins found in prostate cancer cells blocks oncogenic androgen receptor signaling.
         close up of microscope image lighter blue up top looks to be glowing and lower not glowing and more black
    Health Lab

    Inactivation of key pathway boosts the body’s immune response against tumors

    Immunotherapy uses the body’s immune system to recognize and destroy cancer cells. However, many patients are resistant to this therapy, which poses a challenge to their treatment. A study led by researchers from the University of Michigan showed that targeting CDK12/13 improves the effectiveness of cancer therapies.